266 related articles for article (PubMed ID: 37426648)
1. Effectiveness and cost-effectiveness of human papillomavirus vaccination strategies among men who have sex with men in China: a modeling study.
Li Y; Lin YF; Wu X; Zhou X; Tian T; Guo Z; Fu L; Yang L; Lu Z; Fan S; Lu Y; Ke W; Zou H
Front Immunol; 2023; 14():1197191. PubMed ID: 37426648
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
[TBL] [Abstract][Full Text] [Related]
3. Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia.
Deshmukh AA; Chiao EY; Das P; Cantor SB
Vaccine; 2014 Dec; 32(51):6941-6947. PubMed ID: 25444820
[TBL] [Abstract][Full Text] [Related]
4. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis.
Kim JJ
Lancet Infect Dis; 2010 Dec; 10(12):845-52. PubMed ID: 21051295
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
Lee VJ; Tay SK; Teoh YL; Tok MY
BMC Public Health; 2011 Mar; 11():203. PubMed ID: 21453537
[TBL] [Abstract][Full Text] [Related]
6. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
7. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
[TBL] [Abstract][Full Text] [Related]
8. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
Westra TA; Stirbu-Wagner I; Dorsman S; Tutuhatunewa ED; de Vrij EL; Nijman HW; Daemen T; Wilschut JC; Postma MJ
BMC Infect Dis; 2013 Feb; 13():75. PubMed ID: 23390964
[TBL] [Abstract][Full Text] [Related]
9. Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness.
Soe NN; Ong JJ; Ma X; Fairley CK; Latt PM; Jing J; Cheng F; Zhang L
Hum Vaccin Immunother; 2018; 14(12):3010-3018. PubMed ID: 30024823
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Outcomes of Adding HPV Vaccine to the Anal Intraepithelial Neoplasia Treatment Regimen in HIV-Positive Men Who Have Sex With Men.
Deshmukh AA; Chhatwal J; Chiao EY; Nyitray AG; Das P; Cantor SB
Clin Infect Dis; 2015 Nov; 61(10):1527-35. PubMed ID: 26223993
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
12. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.
Boiron L; Joura E; Largeron N; Prager B; Uhart M
BMC Infect Dis; 2016 Apr; 16():153. PubMed ID: 27084683
[TBL] [Abstract][Full Text] [Related]
13. Human Papillomavirus associated prevention: knowledge, attitudes, and perceived risks among men who have sex with men and transgender women in Pakistan: a qualitative study.
Ejaz M; Ekström AM; Ahmed A; Haroon A; Ali D; Ali TS; Salazar M
BMC Public Health; 2022 Feb; 22(1):378. PubMed ID: 35193544
[TBL] [Abstract][Full Text] [Related]
14. Impact and Cost-effectiveness of Selective Human Papillomavirus Vaccination of Men Who Have Sex With Men.
Lin A; Ong KJ; Hobbelen P; King E; Mesher D; Edmunds WJ; Sonnenberg P; Gilson R; Bains I; Choi YH; Tanton C; Soldan K; Jit M
Clin Infect Dis; 2017 Mar; 64(5):580-588. PubMed ID: 28011615
[TBL] [Abstract][Full Text] [Related]
15. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
[TBL] [Abstract][Full Text] [Related]
16. Potential effectiveness of prophylactic HPV immunization for men who have sex with men in the Netherlands: A multi-model approach.
Bogaards JA; Mooij SH; Xiridou M; Schim van der Loeff MF
PLoS Med; 2019 Mar; 16(3):e1002756. PubMed ID: 30830901
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: The time is now.
Deshmukh AA; Cantor SB; Fenwick E; Chiao EY; Nyitray AG; Stier EA; Goldstone SE; Wilkin T; Chhatwal J
Vaccine; 2017 Sep; 35(38):5102-5109. PubMed ID: 28807605
[TBL] [Abstract][Full Text] [Related]
18. Targeted human papillomavirus vaccination for young men who have sex with men in Australia yields significant population benefits and is cost-effective.
Zhang L; Regan DG; Ong JJ; Gambhir M; Chow EPF; Zou H; Law M; Hocking J; Fairley CK
Vaccine; 2017 Sep; 35(37):4923-4929. PubMed ID: 28789853
[TBL] [Abstract][Full Text] [Related]
19. UK healthcare professionals' uncertainties, barriers and facilitators to the introduction of targeted human papillomavirus vaccination for men who have sex with men.
Nadarzynski T; Llewellyn C; Richardson D; Pollard A; Smith H
Sex Health; 2017 Aug; 14(4):372-377. PubMed ID: 28591548
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa.
Michaeli DT; Stoycheva S; Marcus SM; Zhang W; Michaeli JC; Michaeli T
Clin Drug Investig; 2022 Apr; 42(4):333-343. PubMed ID: 35294726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
